American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in ∼1 to 2 individuals per 1000 each year, corresponding to ∼300 000 to 600 000 events in the United States annually. These evidence-based guidelines from the American Society of Hematology (ASH) intend to support patients, clinicians, and others in decisions about treatment of VTE. ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and adult patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment.

Ortel, T, Neumann, I, Ageno, W, Beyth, R, Clark, N.P., Cuker, A, Hutten, B.A., Jaff, M.R., Manja, V, Schulman, S, Thurston, C, Vedantham, S, Verhamme, P, Witt, D.M., Florez, I.D., Izcovich, A, Nieuwlaat, R, Ross, R, Schünemann, H.J., Wiercioch, W, Zhang, Y, Zhang, Y. (2020) American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv  Volume 4, Issue 19. 4693–4738. doi: 10.1182/bloodadvances.2020001830